Department of Radiotherapy and Radiation Oncology, Philipps University, Marburg, Germany.
Clin Colorectal Cancer. 2011 Jun;10(2):121-5. doi: 10.1016/j.clcc.2011.03.009. Epub 2011 Apr 22.
We investigated the role of radiotherapy, including whole brain radiotherapy and stereotactic radiosurgery (SRS), and prognostic factors in patients with colorectal cancer (CRC) who developed brain metastases.
The data of 78 patients who received multidisciplinary treatment from 1996 to 2007 were reviewed. Overall survival (OS), intracerebral control (ICC), and local control (LC) were retrospectively analyzed. Six potential prognostic factors were evaluated: age, gender, number of brain metastases, extracerebral metastases, recursive partitioning analysis (RPA) class, and interval from tumor diagnosis to radiotherapy.
The median OS and ICC for the entire cohort were 8 and 6 months, respectively. Surgical resection-incorporating treatment resulted in significant improvement in OS (P = .036). On multivariate analysis, OS and ICC were significantly correlated with lack of extracerebral metastases (P = .024 and P = .041, respectively), lower number of lesions (P < .001 and P = .007, respectively) and interval from primary CRC diagnosis (P < .001 and .005, respectively) whereas RPA class I-II demonstrated significance only for OS (P = .045). SRS-incorporating therapy revealed a 1-year LC probability of 85%. No association between LC and any of the potential prognostic factors was observed.
Our data indicate that surgery can prolong survival in CRC patients with brain metastases. SRS-incorporating treatment provides excellent LC rates and should be considered for patients with 1-3 lesions. The strong association between survival and the prognostic factors identified in this study highlights a patient subset that may potentially benefit from new, more aggressive therapies.
我们研究了放疗(包括全脑放疗和立体定向放射外科手术)的作用以及在结直肠癌(CRC)患者中发生脑转移的预后因素。
回顾了 1996 年至 2007 年接受多学科治疗的 78 例患者的数据。回顾性分析了总生存(OS)、颅内控制(ICC)和局部控制(LC)。评估了 6 个潜在的预后因素:年龄、性别、脑转移灶数量、颅外转移、递归分区分析(RPA)分级和从肿瘤诊断到放疗的时间间隔。
整个队列的中位 OS 和 ICC 分别为 8 个月和 6 个月。手术切除结合治疗显著改善了 OS(P =.036)。多变量分析显示,OS 和 ICC 与无颅外转移(P =.024 和 P =.041)、病变数量较少(P <.001 和 P =.007)和从原发性 CRC 诊断到放疗的时间间隔较短(P <.001 和 P <.005)显著相关,而 RPA 分级 I-II 仅与 OS 显著相关(P =.045)。SRS 联合治疗可获得 1 年 LC 概率为 85%。LC 与任何潜在的预后因素之间均无相关性。
我们的数据表明,手术可以延长结直肠癌脑转移患者的生存时间。SRS 联合治疗可提供极好的 LC 率,应考虑用于 1-3 个病变的患者。生存与本研究中确定的预后因素之间的强相关性突出了可能受益于新的、更具侵袭性治疗的患者亚组。